^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + brequinar (DUP 785) (DHODH inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
Published date:
05/12/2022
Excerpt:
...we investigated the effects of the DHODH inhibitor brequinar in DHL lymphoma cell lines and the synthetic effects of brequinar and venetoclax. Finally, in vivo study confirmed targeted inhibition of DHODH is synergistic with BCL2 blockade in lymphoma with concurrent MYC and BCL2 rearrangement.
